Logo image of VRCA

VERRICA PHARMACEUTICALS INC (VRCA) Stock Fundamental Analysis

NASDAQ:VRCA - Nasdaq - US92511W1080 - Common Stock - Currency: USD

0.8163  -0.04 (-4.55%)

Premarket: 0.8199 +0 (+0.44%)

Fundamental Rating

2

Overall VRCA gets a fundamental rating of 2 out of 10. We evaluated VRCA against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of VRCA have multiple concerns. While showing a medium growth rate, VRCA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VRCA had negative earnings in the past year.
VRCA had a negative operating cash flow in the past year.
VRCA had negative earnings in each of the past 5 years.
In the past 5 years VRCA always reported negative operating cash flow.
VRCA Yearly Net Income VS EBIT VS OCF VS FCFVRCA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

VRCA has a worse Return On Assets (-156.46%) than 84.54% of its industry peers.
Industry RankSector Rank
ROA -156.46%
ROE N/A
ROIC N/A
ROA(3y)-92.78%
ROA(5y)-75.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRCA Yearly ROA, ROE, ROICVRCA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

VRCA has a better Gross Margin (71.60%) than 80.41% of its industry peers.
The Profit Margin and Operating Margin are not available for VRCA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRCA Yearly Profit, Operating, Gross MarginsVRCA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

1

2. Health

2.1 Basic Checks

VRCA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VRCA has been increased compared to 1 year ago.
The number of shares outstanding for VRCA has been increased compared to 5 years ago.
The debt/assets ratio for VRCA is higher compared to a year ago.
VRCA Yearly Shares OutstandingVRCA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VRCA Yearly Total Debt VS Total AssetsVRCA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

VRCA has an Altman-Z score of -13.64. This is a bad value and indicates that VRCA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of VRCA (-13.64) is worse than 75.26% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.64
ROIC/WACCN/A
WACC12.78%
VRCA Yearly LT Debt VS Equity VS FCFVRCA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

VRCA has a Current Ratio of 1.34. This is a normal value and indicates that VRCA is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of VRCA (1.34) is worse than 74.74% of its industry peers.
A Quick Ratio of 1.26 indicates that VRCA should not have too much problems paying its short term obligations.
VRCA has a Quick ratio of 1.26. This is in the lower half of the industry: VRCA underperforms 68.04% of its industry peers.
Industry RankSector Rank
Current Ratio 1.34
Quick Ratio 1.26
VRCA Yearly Current Assets VS Current LiabilitesVRCA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 31.43% over the past year.
VRCA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.46%.
The Revenue for VRCA have been decreasing by -14.25% on average. This is quite bad
EPS 1Y (TTM)31.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.27%
Revenue 1Y (TTM)-19.46%
Revenue growth 3Y-14.25%
Revenue growth 5YN/A
Sales Q2Q%-10.56%

3.2 Future

The Earnings Per Share is expected to grow by 23.11% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 100.88% on average over the next years. This is a very strong growth
EPS Next Y80.64%
EPS Next 2Y35.92%
EPS Next 3Y24.73%
EPS Next 5Y23.11%
Revenue Next Year138.35%
Revenue Next 2Y107.16%
Revenue Next 3Y89.18%
Revenue Next 5Y100.88%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VRCA Yearly Revenue VS EstimatesVRCA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
VRCA Yearly EPS VS EstimatesVRCA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 1 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VRCA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VRCA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRCA Price Earnings VS Forward Price EarningsVRCA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRCA Per share dataVRCA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

VRCA's earnings are expected to grow with 24.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.92%
EPS Next 3Y24.73%

More info and screens

0

5. Dividend

5.1 Amount

VRCA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERRICA PHARMACEUTICALS INC

NASDAQ:VRCA (7/18/2025, 8:19:08 PM)

Premarket: 0.8199 +0 (+0.44%)

0.8163

-0.04 (-4.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-12 2025-08-12
Inst Owners31.9%
Inst Owner Change1.21%
Ins Owners35.41%
Ins Owner Change-0.01%
Market Cap75.50M
Analysts78.18
Price Target4.08 (399.82%)
Short Float %3.34%
Short Ratio3.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.91%
Min EPS beat(2)-0.55%
Max EPS beat(2)10.36%
EPS beat(4)2
Avg EPS beat(4)-1.63%
Min EPS beat(4)-30.9%
Max EPS beat(4)14.57%
EPS beat(8)3
Avg EPS beat(8)-9.02%
EPS beat(12)6
Avg EPS beat(12)7.66%
EPS beat(16)9
Avg EPS beat(16)10.38%
Revenue beat(2)1
Avg Revenue beat(2)-17.02%
Min Revenue beat(2)-67.61%
Max Revenue beat(2)33.57%
Revenue beat(4)2
Avg Revenue beat(4)-38.89%
Min Revenue beat(4)-137.73%
Max Revenue beat(4)33.57%
Revenue beat(8)6
Avg Revenue beat(8)75.1%
Revenue beat(12)7
Avg Revenue beat(12)40.75%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)20%
EPS NQ rev (1m)5.37%
EPS NQ rev (3m)14.55%
EPS NY rev (1m)-8.47%
EPS NY rev (3m)3.36%
Revenue NQ rev (1m)-2.29%
Revenue NQ rev (3m)16.18%
Revenue NY rev (1m)-2.44%
Revenue NY rev (3m)16.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.52
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.2
EYN/A
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.08
BVpS-0.2
TBVpS-0.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -156.46%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.6%
FCFM N/A
ROA(3y)-92.78%
ROA(5y)-75.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.34
Quick Ratio 1.26
Altman-Z -13.64
F-Score2
WACC12.78%
ROIC/WACCN/A
Cap/Depr(3y)37.37%
Cap/Depr(5y)830.75%
Cap/Sales(3y)3.58%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.27%
EPS Next Y80.64%
EPS Next 2Y35.92%
EPS Next 3Y24.73%
EPS Next 5Y23.11%
Revenue 1Y (TTM)-19.46%
Revenue growth 3Y-14.25%
Revenue growth 5YN/A
Sales Q2Q%-10.56%
Revenue Next Year138.35%
Revenue Next 2Y107.16%
Revenue Next 3Y89.18%
Revenue Next 5Y100.88%
EBIT growth 1Y25.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.93%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-253.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-260.11%
OCF growth 3YN/A
OCF growth 5YN/A